<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093246</url>
  </required_header>
  <id_info>
    <org_study_id>HMT+UPD CFA</org_study_id>
    <nct_id>NCT03093246</nct_id>
  </id_info>
  <brief_title>Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis</brief_title>
  <official_title>Evaluation of Omega-3 Polyunsaturated Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized controlled clinical trial of superiority will be to evaluate the&#xD;
      effect of 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily&#xD;
      supplementation over a period of 180 days as adjunct to non-surgical therapY of patients with&#xD;
      generalized aggressive periodontitis. Probing depth, clinical attachment level, gingival&#xD;
      index and concentration of microorganisms and cytokines at baseline, 3, and 6 12 months after&#xD;
      the procedure will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study methodology is according to CONSORT-STATEMENT 2010 for randomized controlled&#xD;
      clinical trials.&#xD;
&#xD;
      Study Design The study is designed as a prospective, interventional, parallel, blinded,&#xD;
      randomized, controlled clinical trial of superiority.&#xD;
&#xD;
      Source of data The population of this study will be recruited among patients referred to the&#xD;
      Science and Technology Institute - ICT- São José dos Campos, College of Dentistry. Patients&#xD;
      will fill a healthy history questionnaire to ensure that they are medically qualified for&#xD;
      participate in this study. Based on the power calculation for this study, a population of 38&#xD;
      patients will be included. Considering α of 5% and 10% β-type error (90% power) to detect a&#xD;
      difference of at least 1 mm in probing depth reduction of pockets ≥ 5 mm between groups, for&#xD;
      a standard deviation of 0.94 from a previous study evaluating different antimicrobials in the&#xD;
      treatment of GAgP (Xajigeorgiou et al., 2006), 19 patients will be needed in each group.&#xD;
&#xD;
      Clinical Parameters All clinical parameters will be assessed by a single blinded, trained and&#xD;
      calibrated examiner (CFA) before periodontal therapy (baseline) and at 3 and 6 months after&#xD;
      using a manual probe. Measurements will be done at six sites per tooth (mesiobuccal, buccal,&#xD;
      disto-buccal, distolingual, lingual, and mesiolingual) in all teeth, except third molars.&#xD;
&#xD;
      The following clinical parameters will be evaluated: 1) Full-mouth plaque index (FMPI); 2)&#xD;
      Bleeding on probing (BoP); 3) Probing depth (PD): distance from the bottom of sulcus/pocket&#xD;
      to gingival margin; 4) Gingival recession (GM): distance from the free gingival margin to&#xD;
      cement-enamel junction (CEJ); 5) Clinical attachment level (CAL): distance from bottom of&#xD;
      sulcus/pocket to the CEJ. The CEJ will be identified by careful probe on cervical area.&#xD;
&#xD;
      Calibration and Randomization Initially, a total of ten patients presenting with GAgP will be&#xD;
      selected. The designated examiner (CFA) will measure CAL and PD in all patients twice within&#xD;
      24 hours, with an interval of ≥ 1 hour between examinations. Then, the measures will be&#xD;
      submitted to intraclass correlation test and the examiner will be judged calibrated if&#xD;
      reaches 90% agreement.&#xD;
&#xD;
      Patients will be allocated into two groups according to a computer-generated list. The&#xD;
      allocation will be implemented by an investigator (NC) who was not directly involved in the&#xD;
      examination or treatment procedures.&#xD;
&#xD;
      Treatment Protocols&#xD;
&#xD;
      All patients will be treated with periodontal therapy through of the one-stage, full mouth,&#xD;
      ultrasonic debridement (FMUD). In a single session, patients will receive local anesthesia&#xD;
      and periodontal debridement with ultrasound equipment (Cavitron - Dentsply EUA) and&#xD;
      subgingival tips (UI25KSF10S, Hu-Friedy). All diseased sites will be instrumented in this one&#xD;
      session. The debridement session will be performed by a single experienced and trained&#xD;
      periodontist (NA), different from the examiner. Immediately before the mechanical therapy,&#xD;
      patients will be allocated in one of the two treatment protocols:&#xD;
&#xD;
      Test group (n = 19): FMUD + 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin&#xD;
      daily supplementation over a period of 180 days; Control group (n = 19): FMUD + placebo&#xD;
      pills.&#xD;
&#xD;
      All patients will start taking the pills immediately before of the FMUD session.&#xD;
&#xD;
      Microbiological evaluation Subgingival microbiological samples will be collected at the&#xD;
      baseline, 3 and 6 months after therapy. The site will be isolated with a sterile cotton&#xD;
      roller and supragingival biofilm will be carefully removed with periodontal curettes and a&#xD;
      sterile paper will be inserted into the periodontal pocket for 30 s (Hartoth et al., 1999).&#xD;
      The sample will be stored in sterile microtubes. The samples will then be lyophilized and&#xD;
      sent to the Department of Periodontology at the University of Florida, where the samples will&#xD;
      be analyzed.&#xD;
&#xD;
      Evaluation of cytokines For the analysis of immunological changes, crevicular gingival fluid&#xD;
      (CGF) will be collected at baseline, 3 and 6 months after treatment. Each site will be&#xD;
      isolated with a sterile cotton roller and the supragingival biofilm will be removed. After&#xD;
      this, the CGF will be collected with Periopaper strips (Periopaper, Oraflow, Plainview, NY,&#xD;
      USA), inserted in the pocket for 15 seconds. The volume of collected fluid will be measured&#xD;
      (Periotron 8000, Oraflow). The Periopaper strips will be stored in a sterile tube containing&#xD;
      300μl of phosphate saline (PBS) with 5% Tween-20 and stored in a freezer at -20 ° C until the&#xD;
      multiplex test. The level of the following cytokines will be measured in the CGF: interferon&#xD;
      (IFN) -γ, interleukins (IL) -10, -1β, -4, -6, -8, tumor necrosis factor (TNF) -α, macrophage&#xD;
      inflammatory protein 1α (MIP1α), 1α monocyte chemotactic protein (MCP-1α). The 10-plex high&#xD;
      sensitivity kit (Millipore Corporation, Billerica, MA, USA) will be used according to the&#xD;
      manufacturer's instruction and analyzed using the MAGpixTM platform (MiraiBio, Alameda, CA,&#xD;
      USA). Samples will be analyzed individually (each pocket separately) and the concentrations&#xD;
      will be calculated using a standard 5-parameter curve in the Xponet program (Millipore&#xD;
      Corporation). The concentration of each marker will be given in pg / ml. All analysis of&#xD;
      cytokine concentrations will be done in duplicate.&#xD;
&#xD;
      Statistical analysis Two analyzes will be performed: Per Protocol and Intention-to-treat&#xD;
      (Moher, 2010; Gupta, 2011; Day, 2008). For each of them, mean and standard deviation will be&#xD;
      calculated in each of the parameters. Full-mouth PI, GI, PD, CAL, and GR will be submitted to&#xD;
      the Shapiro-Wilk test to evaluate the distribution of these data, and then subjected to the&#xD;
      variance test for both intra- and intra-group comparison. In addition, the number of pockets&#xD;
      ≥ 5mm, the frequency of closure of these pockets, the mean reduction in PS and the gain in&#xD;
      CAL of these pockets will be assessed before and after the therapy by performing intra- and&#xD;
      inter-group analyzes.&#xD;
&#xD;
      The concentration of each cytokine will be analyzed by test of variance for intra and&#xD;
      intergroup comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Probing Depth</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Evaluate the difference between baseline and 6 months PD measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Attachment Level</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Evaluate the difference between baseline and 6 months CAL measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bleeding on Probe</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Evaluate the difference between baseline and 6 months BoP measures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Aggressive Periodontitis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 polyunsaturated fatty acids</intervention_name>
    <description>3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days</description>
    <arm_group_label>Test Group</arm_group_label>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100 mg of aspirin daily supplementation over a period of 180 days</description>
    <arm_group_label>Test Group</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills over a period of 180 days</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full-mouth ultrasonic debridement</intervention_name>
    <description>Full-mouth ultrasonic debridement will be performed in order to treat diseased sites</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test Group</arm_group_label>
    <other_name>Periodontal debridement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of GAgP (AAP, 1999);&#xD;
&#xD;
          -  presence of ≥20 teeth;&#xD;
&#xD;
          -  presence of ≥ 6 sites presenting PD ≥ 5mm with bleeding on probing (BOP) and ≥2 sites&#xD;
             with PD ≥7mm (including incisors and first molars, in addition to other two&#xD;
             non-contiguous teeth);&#xD;
&#xD;
          -  good general health;&#xD;
&#xD;
          -  agree to participate in the study and sign a written informed consent. All subjects&#xD;
             will be individually informed about the objectives, probable risks and benefits of the&#xD;
             protocol treatment (according to Resolution nº196 of October 1996 and to the&#xD;
             Professional Code of Dental Ethics - 179/93).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or lactating;&#xD;
&#xD;
          -  suffer from any systemic disease (e.g. cardiovascular disorders, diabetes, blood&#xD;
             dyscrasias, immunodeficiency, etc) which could alter the course of periodontal&#xD;
             disease;&#xD;
&#xD;
          -  took antimicrobials in the previous 6 months;&#xD;
&#xD;
          -  taking long-term anti-inflammatory drugs;&#xD;
&#xD;
          -  previous periodontal treatment within the last 12 months;&#xD;
&#xD;
          -  smoker ≥ 10 cigarettes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Santamaria, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Estadual Paulista &quot;Julio de Mesquita Filho&quot;, ICT/UNESP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Dentistry - São José dos Campos, Sao Paulo State University</name>
      <address>
        <city>Sao Jose dos Campos</city>
        <state>SP</state>
        <zip>12245-310</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>El-Sharkawy H, Aboelsaad N, Eliwa M, Darweesh M, Alshahat M, Kantarci A, Hasturk H, Van Dyke TE. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin. J Periodontol. 2010 Nov;81(11):1635-43. doi: 10.1902/jop.2010.090628. Epub 2010 Jun 23.</citation>
    <PMID>20572767</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <results_first_submitted>May 24, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Mauro Pedrine Santamaria</investigator_full_name>
    <investigator_title>PhD Adjunt professor</investigator_title>
  </responsible_party>
  <keyword>Full-mouth ultrasonic debridement</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Omega-3 polyunsaturated fatty acids</keyword>
  <keyword>Non-surgical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Aggressive Periodontitis</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03093246/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>In this group (n = 19), patients took placebo pills and full-mouth ultrasonic debridement was performed to treat diseased sites.&#xD;
Placebo: Placebo pills over a period of 180 days&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites</description>
        </group>
        <group group_id="P2">
          <title>Test Group</title>
          <description>In this group (n = 19), patients took 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.&#xD;
Omega-3 polyunsaturated fatty acids: 900 mg of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days&#xD;
Aspirin: 100 mg of aspirin daily supplementation over a period of 180 days&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>In this group (n = 19), patients received placebo pills over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.</description>
        </group>
        <group group_id="B2">
          <title>Test Group</title>
          <description>In this group (n = 19), patients received 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.42" spread="5.79"/>
                    <measurement group_id="B2" value="32.84" spread="5.47"/>
                    <measurement group_id="B3" value="31.63" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Probing Depth</title>
        <description>Evaluate the difference between baseline and 6 months PD measures.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>In this group (n = 19), patients took placebo pills over a period of 180 days and received full-mouth ultrasonic debridement to treat diseased sites.</description>
          </group>
          <group group_id="O2">
            <title>Test Group</title>
            <description>In this group (n = 19), patients will take 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Probing Depth</title>
          <description>Evaluate the difference between baseline and 6 months PD measures.</description>
          <units>milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.15"/>
                    <measurement group_id="O2" value="3.74" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.14"/>
                    <measurement group_id="O2" value="3.26" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.14"/>
                    <measurement group_id="O2" value="3.25" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Generalized Estimated Equations</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Attachment Level</title>
        <description>Evaluate the difference between baseline and 6 months CAL measures.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>In this group (n = 19), patients took placebo pills over a period of 180 days and received full-mouth ultrasonic debridement to treat diseased sites.</description>
          </group>
          <group group_id="O2">
            <title>Test Group</title>
            <description>In this group (n = 19), patients will take 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Attachment Level</title>
          <description>Evaluate the difference between baseline and 6 months CAL measures.</description>
          <units>milimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="0.17"/>
                    <measurement group_id="O2" value="4.01" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.17"/>
                    <measurement group_id="O2" value="3.65" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="0.17"/>
                    <measurement group_id="O2" value="3.64" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Generalized Estimated Equations</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bleeding on Probe</title>
        <description>Evaluate the difference between baseline and 6 months BoP measures</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>In this group (n = 19), patients took placebo pills over a period of 180 days and received full-mouth ultrasonic debridement to treat diseased sites.</description>
          </group>
          <group group_id="O2">
            <title>Test Group</title>
            <description>In this group (n = 19), patients will take 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bleeding on Probe</title>
          <description>Evaluate the difference between baseline and 6 months BoP measures</description>
          <units>percentage of sites with BoP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.11" spread="4.97"/>
                    <measurement group_id="O2" value="44.58" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.27" spread="3.72"/>
                    <measurement group_id="O2" value="27.41" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.77" spread="3.58"/>
                    <measurement group_id="O2" value="26.17" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Generalized Estimated Equations</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>In this group (n = 19), patients took placebo pills over a period of 180 days and received full-mouth ultrasonic debridement to treat diseased sites.</description>
        </group>
        <group group_id="E2">
          <title>Test Group</title>
          <description>In this group (n = 19), patients will take 900 mg of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement was performed to treat diseased sites.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Mauro Pedrine Santamaria</name_or_title>
      <organization>São Paulo State University - Unesp</organization>
      <phone>+5516981937777</phone>
      <email>mauro.santamaria@unesp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

